A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Phase of Trial: Phase III
Latest Information Update: 26 Oct 2016
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ASTRAL-5
- Sponsors Gilead Sciences
- 05 Jul 2016 Status changed from active, no longer recruiting to completed.
- 17 Apr 2016 Interim results (n=106) presented at The International Liver Congress™ 2016
- 16 Apr 2016 Data were presented at The International Liver Congress 2016, according to a Gilead Sciences media release.